Personalized therapeutics for levofloxacin: a focus on pharmacokinetic concerns

References

• International Pharmaceutical FederationTowards a future vision for complex patients Available from: http://www.fip.org/dublin2013/Dublin/2041/ProGramme/Accessed December 4, 2013
   Google Scholar
• MorelloCMHirschJDLeeKCNavigating complex patients using an innovative tool: the MTM Spider WebJ Am Pharm Assoc (2003)20135353053824030131
   PubMed Web of Science ®Google Scholar
• Joint Commission InternationalJCI accreditation standards for hospitalsOak Brook, IL, USAJoint Commission International2010 Available from: http://www.jointcommissioninternational.org/common/pdfs/jcia/IAS400_Standards_Lists_Only.pdfAccessed March 20, 2013
   Google Scholar
• LiWZhouQPatient diagnosis on electronic prescription orders: a key element for appropriateness review by pharmacistsRes Social Adm Pharm2013949349423890197
   PubMed Web of Science ®Google Scholar
• ZhuLLZhouQIntervention for improving the appropriateness of physician orders for oral medications in geriatric VIP patients during the journey to JCI accreditationTher Clin Risk Manag2013927327523761971
   PubMed Web of Science ®Google Scholar
• McGregorJCAllenGPBeardenDTLevofloxacin in the treatment of complicated urinary tract infections and acute pyelonephritisTher Clin Risk Manag2008484385319209267
   PubMedGoogle Scholar
• GiordanoPWeberKGesinGKubertJSkin and skin structure infections: treatment with newer generation fluoroquinolonesTher Clin Risk Manag2007330931718360639
   PubMedGoogle Scholar
• PrajapatiAGangulyBAppropriateness of drug dose and frequency in patients with renal dysfunction in a tertiary care hospital: a cross-sectional study20135136140
   Google Scholar
• NicolauDPPredicting antibacterial response from pharmacodynamic and pharmacokinetic profilesInfection200129Suppl 2111511785851
   PubMed Web of Science ®Google Scholar
• LabrecheMJFreiCRDeclining susceptibilities of Gram-negative bacteria to the fluoroquinolones: effects on pharmacokinetics, pharmacodynamics, and clinical outcomesAm J Health Syst Pharm2012691863187023111670
   PubMed Web of Science ®Google Scholar
• DrusanoGLPrestonSLFowlerCCorradoMWeisingerBKahnJRelationship between fluoroquinolone area under the curve: minimum inhibitory concentration ratio and the probability of eradication of the infecting pathogen, in patients with nosocomial pneumoniaJ Infect Dis20041891590159715116294
   PubMed Web of Science ®Google Scholar
• DefifeRScheetzMHFeinglassJMPostelnickMJScarsiKKEffect of differences in MIC values on clinical outcomes in patients with bloodstream infections caused by Gram-negative organisms treated with levofloxacinAntimicrob Agents Chemother2009531074107919075047
   PubMed Web of Science ®Google Scholar
• AndersonVRPerryCMLevofloxacin: a review of its use as a high-dose, short-course treatment for bacterial infectionDrugs20086853556518318569
   PubMed Web of Science ®Google Scholar
• NoreddinAMElkhatibWFCunnionKMZhanelGGCumulative clinical experience from over a decade of use of levofloxacin in community-acquired pneumonia: critical appraisal and role in therapyDrug Healthc Patient Saf20113596822046107
   PubMedGoogle Scholar
• CookAMMartinCAdamsVRMoreheadRSPharmacokinetics of intravenous levofloxacin administered at 750 milligrams in obese adultsAntimicrob Agents Chemother2011553240324321576432
   PubMed Web of Science ®Google Scholar
• PaiMPAllenSEAmsdenGWAltered steady state pharmacokinetics of levofloxacin in adult cystic fibrosis patients receiving calcium carbonateJ Cyst Fibros2006515315716481224
   PubMed Web of Science ®Google Scholar
• OverholserBRKaysMBLagvankarSGoldmanMMuellerBASowinskiKMPharmacokinetics of intravenously administered levofloxacin in men and womenPharmacotherapy2005251310131816185174
   PubMed Web of Science ®Google Scholar
• ChienSWellsTGBlumerJLLevofloxacin pharmacokinetics in childrenJ Clin Pharmacol20054515316015647407
   PubMed Web of Science ®Google Scholar
• NoreddinAMHobanDJZhanelGGComparison of gatifloxacin and levofloxacin administered at various dosing regimens to hospitalised patients with community-acquired pneumonia: pharmacodynamic target attainment study using North American surveillance data for Streptococcus pneumoniaeInt J Antimicrob Agents20052612012516046101
   PubMed Web of Science ®Google Scholar
• PeaFDi QualECusenzaABrolloLBaldassarreMFurlanutMPharmacokinetics and pharmacodynamics of intravenous levofloxacin in patients with early-onset ventilator-associated pneumoniaClin Pharmacokinet20034258959812793843
   PubMed Web of Science ®Google Scholar
• PrestonSLDrusanoGLBermanALLevofloxacin population pharmacokinetics and creation of a demographic model for prediction of individual drug clearance in patients with serious community-acquired infectionAntimicrob Agents Chemother199842109811049593134
   PubMed Web of Science ®Google Scholar
• JansonBThurskyKDosing of antibiotics in obesityCurr Opin Infect Dis20122563464923041773
   PubMed Web of Science ®Google Scholar
• LuqueSGrauSValleMColinoCIFerrerALevofloxacin weight-adjusted dosing and pharmacokinetic disposition in a morbidly obese patientJ Antimicrob Chemother2011661653165421474480
   PubMed Web of Science ®Google Scholar
• KeesMGWeberSKeesFHorbachTPharmacokinetics of moxifloxacin in plasma and tissue of morbidly obese patientsJ Antimicrob Chemother2011662330233521729931
   PubMed Web of Science ®Google Scholar
• ReyETréluyerJMPonsGDrug disposition in cystic fibrosisClin Pharmacokinet1998353133299812180
   PubMed Web of Science ®Google Scholar
• HurleyMSmythAFluoroquinolones in the treatment of bronchopulmonary disease in cystic fibrosisTher Adv Respir Dis2012636337322968160
   PubMed Web of Science ®Google Scholar
• LeeCKBoyleMPDiener-WestMBrass-ErnstLNoscheseMZeitlinPLLevofloxacin pharmacokinetics in adult cystic fibrosisChest200713179680217356095
   PubMed Web of Science ®Google Scholar
• GellerDEFlumePAStaabDFischerRLoutitJSConradDJMpex 204 Study GroupLevofloxacin inhalation solution (MP-376) in patients with cystic fibrosis with Pseudomonas aeruginosaAm J Respir Crit Care Med20111831510151621471106
   PubMed Web of Science ®Google Scholar
• AlmeidaSFilipeAAlmeidaAWongHCaparrósNTanguayMComparative bioavailability of two formulations of levofloxacin and effect of sex on bioequivalence analysis. Data from a randomised, 2 × 2 crossover trial in healthy volunteersArzneimittelforschung20055541441916080281
   PubMed Web of Science ®Google Scholar
• ChienSCChowATNatarajanJAbsence of age and gender effects on the pharmacokinetics of a single 500-milligram oral dose of levofloxacin in healthy subjectsAntimicrob Agents Chemother199741156215659210685
   PubMed Web of Science ®Google Scholar
• Food and Drug AdministrationLevaquin medication guide Available from: http://www.fda.gov/downloads/Drugs/.../UCM133684.pdfAccessed December 4, 2013
   Google Scholar
• BaileyAMWeantKABakerSNPrevalence and risk factor analysis of resistant Escherichia coli urinary tract infections in the emergency departmentPharm Pract (Granada)2013119610124155856
   PubMedGoogle Scholar
• TanigawaraYNomuraHKagimotoNOkumuraKHoriRPremarketing population pharmacokinetic study of levofloxacin in normal subjects and patients with infectious diseasesBiol Pharm Bull1995183153207742805
   PubMed Web of Science ®Google Scholar
• TayabZRHochhausGKaufmannSJägerDBarthJDo intensive care patients need an individualized dosing regimen for levofloxacin?Int J Clin Pharmacol Ther20064426226916800098
   PubMed Web of Science ®Google Scholar
• RebuckJAFishDNAbrahamEPharmacokinetics of intravenous and oral levofloxacin in critically ill adults in a medical intensive care unitPharmacotherapy2002221216122512389872
   PubMed Web of Science ®Google Scholar
• Sánchez NavarroAColino GandarillasCIAlvarez LermaFMenachoYADomínguez-GilAPharmacokinetics and pharmacodynamics of levofloxacin in intensive care patientsClin Pharmacokinet20054462763515910010
   PubMed Web of Science ®Google Scholar
• ChienSCRoggeMCGisclonLGPharmacokinetic profile of levofloxacin following once-daily 500-milligram oral or intravenous dosesAntimicrob Agents Chemother199741225622609333057
   PubMed Web of Science ®Google Scholar
• YenYHChenHYWuan-JinLLinYMShenWCChengKJClinical and economic impact of a pharmacist-managed iv-to-po conversion service for levofloxacin in TaiwanInt J Clin Pharmacol Ther20125013614122257579
   PubMed Web of Science ®Google Scholar
• DeguchiTSeikeKYasudaMMatsumotoTEvaluation by Monte Carlo simulation of levofloxacin dosing for complicated urinary tract infections caused by Escherichia coli or Pseudomonas aeruginosaJ Infect Chemother20111772673021409530
   PubMed Web of Science ®Google Scholar
• LeeLJHafkinBLeeIDHohJDixREffects of food and sucralfate on a single oral dose of 500 milligrams of levofloxacin in healthy subjectsAntimicrob Agents Chemother199741219622009333047
   PubMed Web of Science ®Google Scholar
• AmsdenGWWhitakerAMJohnsonPWLack of bioequivalence of levofloxacin when coadministered with a mineral-fortified breakfast of juice and cerealJ Clin Pharmacol20034399099512971031
   PubMed Web of Science ®Google Scholar
• WallaceAWVictoryJMAmsdenGWLack of bioequivalence when levofloxacin and calcium-fortified orange juice are coadministered to healthy volunteersJ Clin Pharmacol20034353954412751275
   PubMed Web of Science ®Google Scholar
• AltintasROguzFBeyturAEdizCGunesAOzerAComparison of results after flouroquinolones and combination therapies in type IIIA chronic prostatitisActas Urol Esp20133761962423768504
   PubMed Web of Science ®Google Scholar
• QinGDXiaoMZZhouYDTamsulosin alters levofloxacin pharmacokinetics in prostates derived from rats with acute bacterial prostatitisAsian J Androl20131525426023353720
   PubMed Web of Science ®Google Scholar
• CohenKALautenbachEWeinerMGSynnestvedtMGasinkLBCoadministration of oral levofloxacin with agents that impair absorption: impact on antibiotic resistanceInfect Control Hosp Epidemiol20082997597718808343
   PubMed Web of Science ®Google Scholar
• VadlamudiRSSmalliganRDIsmailHMInteraction between warfarin and levofloxacin: case seriesSouth Med J200710072072417639754
   PubMed Web of Science ®Google Scholar
• MoffettBSKimSBomgaarsLRReadmissions for warfarin-related bleeding in pediatric patients after hospital dischargePediatr Blood Cancer2013601503150623606286
   PubMed Web of Science ®Google Scholar
• Mercadal OrfilaGGracia GarcíaBLeiva BadosaEPerayre BadíaMReynaldo MartínezCJodar MasanésRRetrospective assessment of potential interaction between levofloxacin and warfarinPharm World Sci20093122422919067226
   PubMedGoogle Scholar
• GhaswallaPKHarpeSETassoneDSlattumPWWarfarin-antibiotic interactions in older adults of an outpatient anticoagulation clinicAm J Geriatr Pharmacother20121035236023089199
   PubMed Web of Science ®Google Scholar
• ClarkNPDelateTRiggsCSWarfarin interactions with antibiotics in the ambulatory care settingJAMA Intern Med201417440941624445404
   PubMed Web of Science ®Google Scholar
• DooseDRWalkerSAChienSCWilliamsRRNayakRKLevofloxacin does not alter cyclosporine dispositionJ Clin Pharmacol19983890939597565
   PubMed Web of Science ®Google Scholar
• FedericoSCarranoRCaponeDGentileAPalmieroGBasileVPharmacokinetic interaction between levofloxacin and ciclosporin or tacrolimus in kidney transplant recipients: ciclosporin, tacrolimus and levofloxacin in renal transplantationClin Pharmacokinet20064516917516485913
   PubMed Web of Science ®Google Scholar
• MulgaonkarAVenitzJSweetDHFluoroquinolone disposition: identification of the contribution of renal secretory and reabsorptive drug transportersExpert Opin Drug Metab Toxicol2012855356922435536
   PubMed Web of Science ®Google Scholar
• MaedaTTakahashiKOhtsuNIdentification of influx transporter for the quinolone antibacterial agent levofloxacinMol Pharm20074859417274666
   PubMed Web of Science ®Google Scholar
• NaruhashiKTamaiIInoueNActive intestinal secretion of new quinolone antimicrobials and the partial contribution of P-glycoproteinJ Pharm Pharmacol20015369970911370709
   PubMed Web of Science ®Google Scholar
• ItoTYanoITanakaKInuiKITransport of quinolone antibacterial drugs by human P-glycoprotein expressed in a kidney epithelial cell line, LLC-PK1J Pharmacol Exp Ther19972829559609262363
   PubMed Web of Science ®Google Scholar
• MulgaonkarAVenitzJGründemannDSweetDHHuman organic cation transporters 1 (SLC22A1), 2 (SLC22A2), and 3 (SLC22A3) as disposition pathways for fluoroquinolone antimicrobialsAntimicrob Agents Chemother2013572705271123545524
   PubMed Web of Science ®Google Scholar
• OhtaKYImamuraYOkudairaNAtsumiRInoueKYuasaHFunctional characterization of multidrug and toxin extrusion protein 1 as a facilitative transporter for fluoroquinolonesJ Pharmacol Exp Ther200932862863419004926
   PubMed Web of Science ®Google Scholar
• FrankeRMScherkenbachLASparreboomAPharmacogenetics of the organic anion transporting polypeptide 1A2Pharmacogenomics20091033934419290786
   PubMed Web of Science ®Google Scholar
• GongIYKimRBImpact of genetic variation in OATP transporters to drug disposition and responseDrug Metab Pharmacokinet20132841823047721
   PubMed Web of Science ®Google Scholar
• ZhouQRuanZRYuanHXuDHZengSABCB1 gene polymorphisms, ABCB1 haplotypes and ABCG2 c.421c> A are determinants of inter-subject variability in rosuvastatin pharmacokineticsPharmazie20136812913423469685
   PubMed Web of Science ®Google Scholar
• ChristensenMMPedersenRSStageTBA gene-gene interaction between polymorphisms in the OCT2 and MATE1 genes influences the renal clearance of metforminPharmacogenet Genomics20132352653423873119
   PubMed Web of Science ®Google Scholar